New Drug Investment Return Down 12% Since Waxman/Hatch - CBO Report
Executive Summary
The commercial return from marketing a new drug has declined by 12% since the Waxman/Hatch Act was enacted in 1984, the Congressional Budget Office estimates in a July report.
You may also be interested in...
Biosimilars Pathway Seen As Part Of Health Care Reform Debate Next Year
The potential for cost savings from biosimilars is likely to entangle the debate over a pathway for their approval into the discussion on health care reform that will unfold in the next Congress
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011